Indirect Comparisons of the Efficacy of Subcutaneous Epcoritamab Vs Chemoimmunotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma

被引：0
|
作者：
Salles, Gilles [1 ]
Wang, Anthony [2 ]
Mutebi, Alex [3 ]
Alshreef, Abualbishr [2 ]
Davies, Kalatu R. [2 ]
van de Wetering, Gijs [4 ]
Chirikov, Viktor [4 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] AbbVie Inc, N Chicago, IL USA
[3] Genmab, Princeton, NJ USA
[4] Open Hlth, Bethesda, MD USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-158028
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：10934 / 10935
页数：2
相关论文
共 50 条
  • [1] IN AND OUT: THE CONVENIENCE OF SUBCUTANEOUS EPCORITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
    Barnhizer, Tiffanie
    Phillips, Tycel
    Feldman, Tatyana
    Doerr, Thomas
    Sacchi, Mariana
    Magarelli, Gabriella
    ONCOLOGY NURSING FORUM, 2023, 50 (02)
  • [2] Novel subgroup analyses of subcutaneous epcoritamab in patients with relapsed/refractory large B-cell lymphoma
    Lewis, David John
    Lewis, David John
    Thieblemont, Catherine
    Ghesquieres, Herve
    Cheah, Chan Y.
    Clausen, Michael Roost
    Cunningham, David
    Do, Young Rok
    Feldman, Tatyana
    Gasiorowski, Robin
    Jurczak, Wojciech
    Kim, Tae Min
    van der Poel, Marjolein
    Poon, Michelle Limei
    Kilavuz, Nurgul
    Stirner, Mariana Cota
    Soong, David
    Chiu, Christopher W.
    Chen, Menghui
    Sacchi, Mariana
    Elliott, Brian
    Hutchings, Martin
    Lugtenburg, Pieternella
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 11 - 12
  • [3] Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma
    Izutsu, Koji
    Kumode, Takahiro
    Yuda, Junichiro
    Nagai, Hirokazu
    Mishima, Yuko
    Suehiro, Youko
    Yamamoto, Kazuhito
    Fujisaki, Tomoaki
    Ishitsuka, Kenji
    Ishizawa, Kenichi
    Ikezoe, Takayuki
    Nishikori, Momoko
    Akahane, Daigo
    Fujita, Jiro
    Dinh, Minh
    Soong, David
    Noguchi, Hidehisa
    Buchbjerg, Jeppe Klint
    Favaro, Elena
    Fukuhara, Noriko
    CANCER SCIENCE, 2023, 114 (12) : 4643 - 4653
  • [4] Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific Antibody, in Relapsed or Refractory Large B-Cell Lymphoma
    Li, Tommy
    Gibiansky, Leonid
    Parikh, Apurvasena
    Putnins, Matthew
    Chiu, Christopher W.
    Sacchi, Mariana
    Feng, Huaibao
    Ahmadi, Tahamtan
    Gupta, Manish
    Xu, Steven
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2025,
  • [5] Subcutaneous epcoritamab in Japanese patients with relapsed/refractory diffuse large B-cell lymphoma: EPCORE NHL-3 data
    Izutsu, Koji
    Kumode, Takahiro
    Yuda, Junichiro
    Nagai, Hirokazu
    Mishima, Yuko
    Suehiro, Youko
    Yamamoto, Kazuhito
    Fujisaki, Tomoaki
    Ishitsuka, Kenji
    Ishizawa, Kenichi
    Ikezoe, Takayuki
    Nishikori, Momoko
    Akahane, Daigo
    Fujita, Jiro
    Wu, Jun
    Broberg, Per
    Buchbjerg, Jeppe
    Fukuhara, Noriko
    ANNALS OF ONCOLOGY, 2023, 34 : S1389 - S1389
  • [6] Subcutaneous Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma from EPCORE NHL-5
    Mazza, Irit Avivi
    Kim, Won Seog
    Ko, Shen
    Grande, Carlos
    Lavie, David
    Chism, David
    Seliem, Mostafa
    Jeng, Edwin E.
    Joshi, Neha
    Siddani, Satya
    Assaily, Wissam
    Sacchi, Mariana
    Dinh, Minh
    Avigdor, Abraham
    BLOOD, 2023, 142
  • [7] Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma
    Davis, James A.
    Granger, Katelynn
    Sakowski, Alex
    Goodwin, Sara
    Herbst, Amanda
    Smith, Deidra
    Hendrickson, Lindsey
    Nachar, Victoria R.
    EXPERT REVIEW OF HEMATOLOGY, 2023, 16 (12) : 915 - 918
  • [8] Improvements in Patient-Reported Outcomes in Relapsed or Refractory Large B-Cell Lymphoma Patients Treated With Epcoritamab
    Phillips, Tycel
    Lugtenburg, Pieternella
    Kalsekar, Anupama
    Mutebi, Alex
    Wang, Anthony
    Blaedel, Julie
    Kosa, Katherine
    Martin, Susan
    Sacchi, Mariana
    Kilavuz, Nurgul
    Thieblemont, Catherine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (03): : e78 - e87.e2
  • [9] Identification of Optimal Dosing Regimen for Subcutaneous Epcoritamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
    Li, Tommy
    Gibiansky, Leonid
    Parikh, Apurvasena
    Chiu, Christopher W.
    Sacchi, Mariana
    Feng, Huaibao
    Ahmadi, Tahi
    Gupta, Manish
    Xu, Steven
    BLOOD, 2023, 142
  • [10] Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity.
    Clausen, Michael Roost
    Lugtenburg, Pieternella
    Hutchings, Martin
    Johnson, Peter W. M.
    Linton, Kim M.
    Lewis, David John
    Chamuleau, Martine
    Balari, Anna Sureda
    Cunningham, David
    Elliott, Brian
    DeMarco, Dena
    Chen, Kuo-mei
    Mous, Rogier
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345